Compare care options for Major Depressive Disorder

See what we know about each option. We may not have all options. This page does not pick one for you.

Pick up to 4 care options

You can share this page. You do not need an account.

3 selected

What we found

Each option is for Major Depressive Disorder. Research and local care are different facts.

Fluoxetine

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined study populations

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Sep 19, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Research for Major Depressive Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/4

Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Sep 19, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Cognitive Behavioral Therapy

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined population

NIMH Depression · checked Sep 20, 2026

Relationship: source-described CBT relationship for the Need

Scope: need:major-depressive-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Depression. Checked Sep 20, 2026. Scope: need:major-depressive-disorder. Link: https://www.nimh.nih.gov/health/publications/depression

Research for Major Depressive Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

NIMH identifies cognitive behavioral therapy as an evidence-based therapy for depression. This bounded assessment does not compare every option or determine personal suitability.

NIMH Depression · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: need:major-depressive-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Depression. Checked Sep 20, 2026. Scope: need:major-depressive-disorder. Link: https://www.nimh.nih.gov/health/publications/depression

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Sertraline

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined population

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source

Source: DailyMed sertraline (Zoloft) label. Checked Sep 20, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/fda754f6-d0f3-4dce-a17a-927d64f912f7.xml

Research for Major Depressive Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

The current ZOLOFT label reports randomized, double-blind, placebo-controlled studies supporting its MDD evidence scope. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source

Source: DailyMed sertraline (Zoloft) label. Checked Sep 20, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/fda754f6-d0f3-4dce-a17a-927d64f912f7.xml

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Page link: https://everyoption.org/compare/major-depressive-disorder?treatments=fluoxetine%2Ccognitive-behavioral-therapy%2Csertraline